Skip to main content
Equibles
CPHI logo

CPHI · China Pharma Holdings, Inc. · Documents

Track CPHI — free

Use CPHI with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CPHI.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.57 +0.04 (+7.53%) At close · Nov 6
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“As of June 30, 2026, the Company had cash and cash equivalents of $0.3 million and an accumulated deficit of $49.8 million, and the Company's current liabilities exceeded current assets by $5.7 million. In addition, the Company incurred net losses of $2.6 million and had cash outflows from operating activities of $0.08 million for the six months ended June 30, 2026.”
View the 10-Q filed Aug 14, 2026
Market Cap
$22.80M
Shares
43.02M
Volume · Nov 6 41.45K Avg daily vol (3M) 1.81M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $4.14M down 8.5% 10-K filed Apr 1, 2026 Quarterly report FY2026 Q2 Revenue $948.34K down 7.5% 10-Q filed Aug 14, 2026
2026
Oct 30
Proxy statement PRE 14A
Reverse split up to 1:50 proposed for stockholder vote

China Pharma Holdings, Inc. will seek approval on December 22, 2026 for a reverse stock split at a ratio of up to 1:50, election of three independent directors, and Amendment No.4 to its 2010 Long-Term Incentive Plan.

Read from the first part of this long document
4 source passages
Notice is hereby given that the Annual Meeting of Stockholders for the fiscal year ended December 31, 2025 (the “Annual Meeting”) of China Pharma Holdings, Inc., a Nevada corporation, will be held on Tuesday, December 22, 2026, at 9:00 p.m., local time (8:00 a.m., Eastern Time), at Conference Room, 2nd Floor, Jiahai Building, No. 17 Jinpan Road, Haikou, Hainan Province, China 570216, for the following purposes: To consider and approve an amendment to the Articles of Incorporation of the Company to effect a reverse stock split, as needed, at a ratio of up to 1:50, such that every holder of common stock, par value $0.001 per share, of the Company (the “Common Stock”) shall receive one share of Common Stock for pro rata twenty shares of Common Stock held (the “Reverse Stock Split”), based on the ratio that is applied with the range above referenced; To elect three independent director nominees to our Board of Directors to serve until the next annual meeting (for independent directors) and until their successors are elected and qualified; To approve Amendment No.4 to the Company’s Amended and Restated 2010 Long-Term Incentive Plan; Open the document at this passage
Aug 14
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $948.34K ▼ 7.5% Net loss $1.46M Diluted EPS -$0.04
May 15
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $983.54K ▼ 13.4% Net loss $1.14M Diluted EPS -$0.04
Apr 1
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $4.14M ▼ 8.5% Net loss $3.19M Diluted EPS -$0.74
2025
Mar 31
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $4.53M ▼ 35.4% Net loss $4.74M Diluted EPS -$0.27
2024
Apr 1
Annual report 10-K FY2023, ended Dec 31
Annual report for FY2023
Revenue $7.01M ▼ 13.5% Net loss $3.08M Diluted EPS -$0.91
2023
Mar 30
Annual report 10-K FY2022, ended Dec 31
Annual report for FY2022
Revenue $8.1M ▼ 15.9% Net loss $3.97M Diluted EPS -$0.76
2022
Showing 1–50 of 74 documents
Key facts CIK 1106644 CUSIP 16941T401 13F (30d) 3 filings 3 filers Visit website